Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Outbreaks of Foodborne Illness

Outbreaks of Foodborne Illness

                        Investigations of Foodborne Illness Outbreaks
          Public Health Advisories from Investigations of Foodborne Illness Outbreaks
          Food Safety Tips for Consumers & Retailers During an Outbreak of Foodborne Illness
          Food Safety Resources for Produce Shippers and Carriers During a Foodborne Illness Outbreak
          Outbreak Investigation Reports
          How to Report Seafood-Related Toxin and Scombrotoxin Fish Poisoning Illnesses
          About the CORE Network
          CORE Annual Reports
          CORE Publications


                        Foodborne Pathogens Home
          Food
          Recalls, Outbreaks & Emergencies
          Outbreaks of Foodborne Illness
          FDA Investigation of Cronobacter Infections: Powdered Infant Formula (February 2022)Outbreaks of Foodborne Illness FDA Investigation of Cronobacter Infections: Powdered Infant Formula (February 2022)
  
  					Do not use recalled Similac, Alimentum, or EleCare powdered infant formulas produced at Abbott Nutrition’s Sturgis, MI, facility
	
    Subscribe to Email Updates
    Share
    Post
    Linkedin

    Email
    PrintSpanish (Español)

**If you want to check if your powdered formula is part of the recall**, you can enter the product lot code on the bottom of your package on the company’s website.

If you have questions or need information about the recall, you can **Submit Questions/Get Assistance**.

**If your infant is experiencing symptoms** related to *Cronobacter* infection, such as poor feeding, irritability, temperature changes, jaundice, grunting breaths, or abnormal body movements; contact your health care provider to report their symptoms and receive immediate care.

To report an **illness** or **adverse event**, you can

Call an FDA Consumer Complaint Coordinator if you wish to speak directly to a person about your problem.
	Complete an electronic Voluntary MedWatch form online.
	Complete a paper Voluntary MedWatch form that can be mailed to the FDA.**Update on Infant Formula Supplies:**The FDA has announced that it will exercise enforcement discretion with respect to the specific infant formula products, to increase infant formula supplies in the United States.

Companies Receiving Enforcement Discretion for Regular Infant Formula (*These lists will be updated on a regular basis.*)
	Internal Review of Agency Actions Related to the U.S. Infant Formula Supply Now Available
	Infant Formula Main Page


The U.S. Food and Drug Administration (FDA)’s Coordinated Outbreak Response and Evaluation (CORE) Network, along with the Centers for Disease Control and Prevention (CDC) and state and local partners investigated consumer complaints and/or reports received by FDA from 9/20/2021 to 2/24/2022, of illnesses among infants who were reported to have consumed powdered infant formula products from Abbott Nutrition’s Sturgis, MI, facility. Although CORE is no longer investigating this incident, the FDA established an Incident Management Group (IMG) on April 1, 2022, to continue to work on supply chain and food safety issues.

Recommendation

The FDA is advising consumers not to use recalled Similac, Alimentum, or EleCare powdered infant formulas. Recalled products can be identified by the 7 to 9 digit code and expiration date on the bottom of the package (see image below). Products are included in the recall if they have all three items below:

the first two digits of the code are 22 through 37 and
	the code on the container contains K8, SH, or Z2, and
	the expiration date is 4-1-2022 (APR 2022) or later.In addition to products described above, Abbott Nutrition has recalled Similac PM 60/40 with a lot code 27032K80 (can) / 27032K800 (case). At this time, Similac PM 60/40 with lot code 27032K80 (can) / 27032K800 (case) is the only type and lot of this specialty formula being recalled. Additional recall information for the initial recall is available on the FDA website. Parents can also enter their product lot code on the company’s website to check if it is part of the recall.

Certain specialty and metabolic formulas have been tested and released by Abbott Nutrition on a case-by-case basis. Parents and caregivers of infants receiving this specialty and metabolic formula should not reference the recall product description above, but instead should enter the product lot code found at the bottom of their package by using the “Check Lot Number” feature at the bottom of the company’s webpage or by calling Abbott Nutrition at 1-800-881-0876.

**Additional Information for Parents and Caregivers:**

The recalls do not include liquid formula products.

Parents and caregivers should never dilute infant formula and should not make or feed homemade infant formula to infants. Consumers should also avoid purchasing imported formula through online sales, as it has the potential to be counterfeit.

If your regular formula is not available, contact your child’s healthcare provider for recommendations on changing feeding practices.

If you get infant formula through WIC, do not throw the formula out. Instead, you should take it to the store for a refund and exchange or call the company at 1-800-986-8540 to help you. WIC recipients should be able to obtain a different brand of similar formula. Call your local WIC clinic for more guidance. Also see, https://www.fns.usda.gov/wic.


Product Images

Sample Product Image from the FDA Investigation of Cronobacter and Salmonella Complaints about Powdered Infant Formula (February 2022)
Sample Product Image from the FDA Investigation of Cronobacter and Salmonella Complaints about Powdered Infant Formula (February 2022)
Sample Product Image from the FDA Investigation of Cronobacter and Salmonella Complaints about Powdered Infant Formula (February 2022)
Case Counts

Total Adverse Events: 4
Hospitalizations: 4
Reported Deaths: 2*
Illness Onset Date Range: 9/6/2021 – 1/4/2022
States with Adverse Events: MN (1), OH (2), TX (1)
Product Distribution: Nationwide and International
* Two deaths have been reported. *Cronobacter* infection may have contributed to the cause of death for both patients.

Useful Links

**Additional Investigation Information**

U.S. Recall Announcement
	Canadian Recall Announcement
	Abbott Nutrition Recall Site
	Expanded Abbott Nutrition Recall of Similac PM 60/40 Powdered Infant Formula
	CDC Investigation Notice: *Cronobacter* Illnesses Linked to Powdered Infant Formula
	USDA Contact Map**For Industry**

FDA Encourages Importation of Safe Infant Formula and Other Flexibilities to Further Increase Availability
	Guidance for Industry on Infant Formula Enforcement Discretion Policy
	List of Companies Receiving Enforcement Discretion for Infant Formula
	Food Safety Tips for Retailers During an Outbreak
**For Consumers**

Infant Formula Main Page
	*Cronobacter sakazakii*
	Helping Families Find Formula During the Infant Formula Shortage (HHS)
	Tips for Preparing Imported Infant Formula
	Food Safety Tips for Consumers During an Outbreak
	*Cronobacter* and Infant Formula (CDC)
	Infant Formula Safety (USDA)
	Toll-Free Numbers for WIC State Agencies (USDA)
	Who to Contact


Recalled Products

Full List of Recalled Brands
	**The following products are included in the recall if they have all three items below:**

the first two digits of the code are 22 through 37 and
	the code on the container contains K8, SH, or Z2, and
	the expiration date is 4-1-2022 (APR 2022) or later**Similac Products**
Abbott Similac 360 Total Care Infant Formula with Iron
Abbott Similac Advance
Abbott Similac Advance Step-1
Abbott Similac Advance Step-2
Abbott Similac Advance Infant Formula with Iron
Abbott Similac Human Milk Fortifier
Abbott Similac Organic
Abbott Similac Organic with A2 Milk Infant Formula with Iron
Abbott Similac Organic with A2 Milk Toddler Drink
Abbott Similac Organic Toddler with A2 Milk Infant Formula with Iron
Abbott Similac Pro-Advance
Abbott Similac Pro-Advance Infant Formula with Iron
Abbott Similac Pro-Sensitive Infant Formula with Iron
Abbott Similac Pro-Total Comfort Infant Formula with Iron
Abbott Similac Sensitive
Abbott Similac Sensitive Infant Formula with Iron
Abbott Similac Sensitive Lactose Sensitivity
Abbott Similac for Supplementation
Abbott Similac For Spit Up Infant Formula with Iron
Abbott Similac Total Comfort
Abbott Similac Total Comfort Infant Formula with Iron
Abbott Similac EleCare HMO
Abbott Similac EleCare
Abbott EleCare Similac Gold
Abbott EleCare Similac
Abbott Similac PM 60/40 - only lot code 27032K80 (can) / 27032K800 (case)

**Alimentum Products**
Abbott Infant Formula Powder
Abbott Similac Alimentum
Abbott Similac Alimentum Allergies & Colic Hypoallergenic Infant Formula
Abbott Similac Alimentum with 2'-FL HMO
Abbott Similac Alimentum Eye Q Plus
Abbott Similac Alimentum HMO
Abbott Alimentum HMO
Abbott Similac Alimentum infant formula
Abbott Similac Alimentum Infant Formula with Iron
Abbott Similac Alimentum Toddler Drink

**EleCare Products**
Abbott EleCare
Abbott EleCare Amino Acid-Based Powder Infant Formula with Iron
Abbott EleCare Infant Formula Unflavoured
Abbott EleCare Junior Vanilla
Abbott EleCare Jr Similac Vanilla
Abbott EleCare Jr Amino Acid-Based Nutrition Powder Unflavored
Abbott EleCare Jr Amino Acid-Based Nutrition Powder Banana
Abbott EleCare Jr Amino Acid-Based Nutrition Powder Chocolate
Abbott EleCare Similac
Abbott EleCare Similac Gold
Abbott Similac EleCare HMO
Abbott Similac EleCare
EleCare LCP Hypoallergenic

Additional Information for Parents and Caregivers of Infants Receiving Medical Specialty Infant Formulas and Individuals Using Certain Medical Foods

Following the voluntary recall and hold of certain powdered infant formula products produced at the Abbott Nutrition facility in Sturgis, MI, Abbott has committed to completing enhanced testing of stored product batches prior to making release determinations. While the FDA recognizes that Abbott has conducted standard product testing, there were a limited number of samples tested. Additionally, although finished product testing does not eliminate the risk of contamination, the enhanced testing will provide for a greater chance to detect *Cronobacter sakazakii*, if present; however, this enhanced level of testing will take additional time.

In the meantime, the FDA has informed Abbott Nutrition that the agency has no objection to the company immediately releasing product to individuals needing urgent, life-sustaining supplies of the specialty and metabolic formulas listed below on a case-by-case basis. The FDA is concerned that the risk of not having certain specialty and metabolic products available could significantly worsen underlying medical conditions and in some cases pose life-threatening risks for infants and individuals who rely on these products. In these circumstances, the benefit of allowing parents, in consultation with their healthcare providers, to access these products may outweigh the potential risk of bacterial infection.

Abbott has confirmed with the FDA that the company will consider release of these products on a case-by-case basis, depending on product availability and the severity of the individual’s need. Patients and caregivers seeking access to these products should contact Abbott directly to request that a product be made available to them by calling 1-800-881-0876.

It is important for parents and caregivers to understand that any products released on a case-by-case basis at this time were made at Abbott Nutrition’s Sturgis, MI, facility, and that the processes, procedures, and conditions that the FDA observed during its inspection of the Sturgis MI production facility from January 31 – March 18, 2022, raise concerns that powdered infant formula produced at this facility prior to the FDA’s inspection carry a risk of contamination. Therefore, those seeking access should consult with their healthcare provider in considering whether the benefit of consuming such product outweighs the potential risk of bacterial infection in the user’s particular circumstances. Parents and caregivers should continue to work with their medical provider to consider whether comparable alternative products may be appropriate.

Should product released on a case-by-case basis be used, parents and caregiver should pay close attention to the user’s health status and alert a healthcare provider immediately of any change in health status. In the meantime, the FDA is continuing to work diligently to ensure the safe resumption of production of infant formula at Abbott Nutrition’s Sturgis, Michigan facility.

Specialty and Metabolic Formulas that may be Released on a Case-By-Case Basis:
	Glutarex-1
Glutarex-2
Cyclinex-1
Cyclinex-2
Hominex-1
Hominex-2
I-Valex-1
I-Valex-2
Ketonex-1
Ketonex-2
Phenex-1
Phenex-2
Phenex-2 Vanilla
Pro-Phree
Propimex-1
Propimex-2
ProViMin
Calcilo XD
Tyrex-1
Tyrex-2
Similac PM 60/40

It is important to note that these specialty infant formulas and medical foods are not sold in traditional retail stores. These products often require a prescription and are sold through specialty pharmacies and other specialty distribution channels such as medical product suppliers.

Parents and caregivers of infants and children using these products should contact their child’s health care providers if they have questions about the use of these products.

International Product Distribution for Recalled Products

The recall impacts Alimentum, EleCare, and Human Milk Fortifier for markets outside the U.S. No other Abbott Nutrition products distributed outside of the U.S. are affected by this recall. According to the firm, recalled products were distributed to the following countries/locations: Australia, Bahrain, Barbados, Bermuda, Canada, Chile, China, Colombia, Costa Rica, Dominican Republic, Ecuador, Egypt, Guam, Guatemala, Hong Kong, India, Indonesia, Israel, Jordan, Kuwait, Lebanon, Malaysia, Mexico, New Zealand, Oman, Peru, Puerto Rico, Qatar, Saudi Arabia, Singapore, South Africa, Sudan, Taiwan, Thailand, United Arab Emirates, United Kingdom, and Vietnam ANI South.

For additional information, international officials and customers can visit the company’s recall page for contact information.

*Cronobacter*Surveillance

*Cronobacter* infection surveillance is not handled the same way as infection with more common foodborne pathogens, such as *Salmonella* or*E. coli* O157:H7. *Cronobacter* is not nationally notifiable and not reportable except in one state, which means doctors and labs are not required to report cases to their health department. Because *Cronobacter*is not a nationally notifiable pathogen, FDA relies on consumer complaints of illness sent to the Agency and on health care providers informing FDA directly about infants with *Cronobacter*infections. In addition, because *Cronobacter*is not nationally notifiable, whole genome sequencing (WGS) is rarely performed on these isolates. To date, no outbreaks of *Cronobacter*have been detected using WGS.

When single cases of *Cronobacter*are reported, the FDA conducts a thorough review of each complaint, conducts sampling of products, and initiates inspections as appropriate. FDA collaborates with CDC, which has developed a detailed questionnaire specifically for *Cronobacter* infections that is often used by state health departments in instances of *Cronobacter sakazakii*infection.

Previous Updates

Updates February 2022 - June 2022
	**June 23, 2022**

On June 22, 2022, the U.S. Food and Drug Administration provided an update on the steps it has taken, and will continue to take, to ensure that American consumers have access to safe and nutritious infant formula in the coming weeks and months. You can read more by accessing the press release.

In addition, the FDA has created an infographic on how to safely prepare and store powdered infant formula.

Additional information about infant formula and ongoing updates about FDA’s response can be found at www.fda.gov/infantformula.

**May 26, 2022**

On May 24, 2022, the FDA has announced that it will exercise enforcement discretion with respect to specific infant formula products to increase infant formula supplies in the United States. The List of Companies Receiving Enforcement Discretion for Infant Formula will be updated on a regular basis.

**May 17, 2022**

On May 16, 2022, the U.S. District Court for the Western District of Michigan entered a consent decree of permanent injunction between FDA and Abbott Nutrition, as well as three Abbott principals. Under the consent decree Abbott Nutrition will, among other things, take corrective actions following an FDA inspection of its Sturgis, Michigan facility.

The U.S. Department of Health & Human Services also released a Fact Sheet for Helping Families Find Formula During the Infant Formula Shortage.

**May 13, 2022**

The U.S. Food and Drug Administration (FDA)’s Coordinated Outbreak Response and Evaluation (CORE) Network, along with the Centers for Disease Control and Prevention (CDC) and state and local partners investigated consumer complaints and/or reports received by FDA from 9/20/2021 to 2/24/2022, of illnesses among infants who were reported to have consumed powdered infant formula products from Abbott Nutrition’s Sturgis, MI, facility.

On May 12, 2022, CDC announced that its investigation is closed, with no additional cases identified as part of the investigation. Although CORE is no longer investigating this incident, the FDA established an Incident Management Group (IMG) on April 1, 2022, to continue to work on supply chain and food safety issues.

**May 11, 2022**

The U.S. Food and Drug Administration (FDA), along with the Centers for Disease Control and Prevention (CDC) and state and local partners are investigating consumer complaints and/or reports, received from 9/20/2021 to 1/11/2022, of infant illness related to products from Abbott Nutrition’s Sturgis, MI, facility. The four ill patients are reported to have consumed powdered infant formula produced from Abbott Nutrition’s Sturgis, MI, facility.

On May 10, 2022, the U.S. Food and Drug Administration provided an update on its work to increase the availability of infant and specialty formula products. This update was announced with a separate press release.

More information will be provided as it becomes available.

**April 29, 2022**

The U.S. Food and Drug Administration (FDA), along with the Centers for Disease Control and Prevention (CDC) and state and local partners are investigating consumer complaints and/or reports, received from 9/20/2021 to 1/11/2022, of infant illness related to products from Abbott Nutrition’s Sturgis, MI, facility. The four ill patients are reported to have consumed powdered infant formula produced from Abbott Nutrition’s Sturgis, MI, facility.

Following the voluntary recall and hold of certain powdered infant formula products produced at the Abbott Nutrition facility in Sturgis, MI, Abbott has committed to completing enhanced testing of stored product batches prior to making release determinations. While the FDA recognizes that Abbott has conducted standard product testing, there were a limited number of samples tested. Additionally, although finished product testing does not eliminate the risk of contamination, the enhanced testing will provide for a greater chance to detect *Cronobacter sakazakii*, if present; however, this enhanced level of testing will take additional time.

In the meantime, the FDA has informed Abbott Nutrition that the agency has no objection to the company immediately releasing product to individuals needing urgent, life-sustaining supplies of the specialty and metabolic formulas listed below on a case-by-case basis. The FDA is concerned that the risk of not having certain specialty and metabolic products available could significantly worsen underlying medical conditions and in some cases pose life-threatening risks for infants and individuals who rely on these products. In these circumstances, the benefit of allowing parents, in consultation with their healthcare providers, to access these products may outweigh the potential risk of bacterial infection.

Abbott has confirmed with the FDA that the company will consider release of these products on a case-by-case basis, depending on product availability and the severity of the individual’s need. Patients and caregivers seeking access to these products should contact Abbott directly to request that a product be made available to them by calling 1-800-881-0876.

It is important for parents and caregivers to understand that any products released on a case-by-case basis at this time were made at Abbott Nutrition’s Sturgis, MI, facility, and that the processes, procedures, and conditions that the FDA observed during its inspection of the Sturgis MI production facility from January 31 – March 18, 2022, raise concerns that powdered infant formula produced at this facility prior to the FDA’s inspection carry a risk of contamination. Therefore, those seeking access should consult with their healthcare provider in considering whether the benefit of consuming such product outweighs the potential risk of bacterial infection in the user’s particular circumstances. Parents and caregivers should continue to work with their medical provider to consider whether comparable alternative products may be appropriate.

Parents and caregivers who obtain these products should carefully follow Abbott’s preparation instructions as indicated on the product container. Should product released on a case-by-case basis be used, parents and caregiver should pay close attention to the user’s health status and alert a healthcare provider immediately of any change in health status. In the meantime, the FDA is continuing to work diligently to ensure the safe resumption of production of infant formula at Abbott Nutrition’s Sturgis, Michigan facility.

Specialty and Metabolic Formulas that may be Released on a Case-By-Case Basis:

Glutarex-1
	Glutarex-2
	Cyclinex-1
	Cyclinex-2
	Hominex-1
	Hominex-2
	I-Valex-1
	I-Valex-2
	Ketonex-1
	Ketonex-2
	Phenex-1
	Phenex-2
	Phenex-2 Vanilla
	Pro-Phree
	Propimex-1
	Propimex-2
	ProViMin
	Calcilo XD
	Tyrex-1
	Tyrex-2
	Similac PM 60/40More information will be provided as it becomes available.

**March 31, 2022**

The U.S. Food and Drug Administration (FDA), along with the Centers for Disease Control and Prevention (CDC) and state and local partners are investigating consumer complaints and/or reports, received from 9/20/2021 to 1/11/2022, of infant illness related to products from Abbott Nutrition’s Sturgis, MI, facility. The four ill patients are reported to have consumed powdered infant formula produced from Abbott Nutrition’s Sturgis, MI, facility.

The FDA investigators at the Abbott Nutrition facility in Sturgis, MI, collected numerous product and environmental samples:

Five environmental subsamples collected from the Sturgis, MI facility were positive for *Cronobacter sakazakii;* four were detected by the FDA and one was detected through firm-initiated testing. The positive *Cronobacter sakazakii* environmental samples at the Sturgis, MI, facility have been analyzed using Whole Genome Sequencing (WGS), revealing five different strains of *Cronobacter sakazakii*.Product samples collected by FDA at the facility were analyzed for *Cronobacter* by FDA and were found negative.There are no additional FDA samples pending analysis at this time. On March 18, 2022, the FDA inspection at the Abbott Nutrition facility in Sturgis, MI, was completed and a Form 483 was issued that included four observations. The inspectional observations in this Form 483 do not constitute final FDA determinations of whether any condition was or is in violation of the Federal Food, Drug, and Cosmetic Act or any of its implementing regulations. FDA will take appropriate action in the future - if warranted - as we continue to evaluate the 2022 inspectional findings.

At this time, CDC has completed laboratory testing for two clinical samples received related to this investigation. Analysis performed by WGS did not find these samples from patients to be a genetic match to the multiple strains of *Cronobacter* found in the environmental samples obtained from Abbott Nutrition’s Sturgis, MI, facility or to any other clinical isolates in the National Center for Biotechnology Informatics (NCBI) database.

The FDA is working with Abbott Nutrition to better assess the impacts of the recall and understand production capacity at other Abbott facilities that produce some of the impacted brands. We are also working with Abbott Nutrition on safe resumption of production at the Sturgis, MI, facility. We will continue discussion with Abbott Nutrition and other infant formula manufacturers and consider all tools available to support the supply of infant formula products. We are also partnering with the United State Department of Agriculture’s Food and Nutrition Service (FNS) to monitor the impact of the recall on The Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) Program.

**March 22, 2022**

The FDA is releasing the FDA Form 483s from three inspections conducted at Abbott Nutrition’s facility on Sept. 16-24, 2019, Sept. 20-24, 2021, and Jan. 31-March 18, 2022. The inspectional observations in these Form 483s do not constitute final FDA determinations of whether any condition was or is in violation of the Federal Food, Drug, and Cosmetic Act or any of its implementing regulations. The FDA will take appropriate action in the future - if warranted - as we continue to evaluate the 2022 inspectional findings.

Important observations noted in the 2022 Form 483 include, but are not limited to:

[Abbott Nutrition] did not establish a system of process controls covering all stages of processing that was designed to ensure that infant formula does not become adulterated due to the presence of microorganisms in the formula or in the processing environment.
	[Abbott Nutrition] did not ensure that all surfaces that contacted infant formula were maintained to protect infant formula from being contaminated by any source.Once the immediate public health risk is minimized, the FDA will conduct a programmatic review to ensure the maximum effectiveness of agency programs and policies related to infant formula and special medical food complaints, illnesses, and recalls.

Conducting this review is a top priority for the FDA and will be done as efficiently as possible, and we can ensure this effort will not interfere with the immediate recall response activities. We will and must continue focusing on taking all steps possible to protect the health of those who rely on safe powdered infant formula.

**March 15, 2022**

To provide clarity about which products are included in the Abbott Nutrition recall, FDA is publishing a full list of recalled brands that have been included in the initial and expanded recall. Recalled products should no longer be available for sale, but if consumers have these products in their homes, they should check the lot code on the bottom of the package to determine if it is included in the recall.

The FDA is also providing additional information for parents and caregivers of infants receiving medical specialty infant formula and individuals using certain medical foods.

**March 9, 2022**

The *Salmonella* Newport illness previously included in this investigation of complaints and illnesses has been removed. In the early stages of this investigation, FDA included all consumer complaints of illness with exposure to products from the Sturgis, MI, facility. After further investigation, the FDA has determined that there is not enough information to definitively link this illness to powdered infant formula. CDC confirmed that this single *Salmonella*illness is not linked to an outbreak. The FDA and CDC are continuing to monitor for *Salmonella* cases and consumer complaints that may be related to this incident.

**February 28, 2022**

As of February 28, CDC has announced one additional illness of *Cronobacter sakazakii* with exposure to powdered infant formula produced at Abbott Nutrition’s Sturgis, MI facility. *Cronobacter*infection may have been a contributing cause of death for this patient. In total, this investigation includes four reports of *Cronobacter sakazakii* infections in infants (three from FDA complaints and one from a CDC case finding) and one complaint of a *Salmonella*Newport infection in an infant. All five (four *Cronobacter* infections and one *Salmonella* Newport infection) illnesses resulted in hospitalization and *Cronobacter* may have contributed to death in two patients.

The most recent patient was reported to have consumed Abbott Nutrition’s Similac PM 60/40 product with the lot code 27032K800 prior to *Cronobacter sakazakii* infection. FDA and CDC informed the firm of these findings and on February 28, 2022, Abbott Nutrition voluntarily recalled Similac PM 60/40 powdered infant formula with the lot code 27032K800. This is a specialty formula for certain infants who would benefit from lowered mineral intake and was not included in the previous recall. At this time, Similac PM 60/40 with lot code 27032K80 (can) / 27032K800 (case) are the only type and lots of this specialty formula being recalled.

This particular lot of Similac PM 60/40 was distributed to the U.S. and Israel. If your regular formula is not available, contact your child’s healthcare provider for recommendations on changing feeding practices.

We understand that infant formula is the sole source of nutrition for many infants and is an essential product. FDA is working with Abbott Nutrition to better assess the impacts of the recall and understand production capacity at other Abbott facilities that produce some of the impacted brands. We are also working with Abbott Nutrition on safe resumption of production at the Sturgis, MI facility. FDA is continuing to investigate and will update this advisory should additional consumer safety information become available.

**February 25, 2022**

As a result of the ongoing investigation, Abbott Nutrition has recalled certain powdered infant formula products and the FDA is advising consumers not to use recalled Similac, Alimentum, or EleCare powdered infant formulas produced in the Sturgis, MI facility.

We recognize that the Abbott Nutrition recall resulted in consumers seeking alternative brands or types of infant formula and that the recall has created new concerns about the availability of certain types of infant formula, particularly given the overall strains on supply chains experienced during the COVID-19 pandemic.

We understand that infant formula is the sole source of nutrition for many infants and is an essential product.

FDA is working with Abbott Nutrition to better assess the impacts of the recall and understand production capacity at other Abbott facilities that produce some of the impacted brands. We are also working with Abbott Nutrition on safe resumption of production at the Sturgis, MI facility. Throughout the pandemic, FDA has also been monitoring potential supply chain risks for this category of products and has been reaching out to infant formula manufacturers and their trade groups. As Abbott Nutrition was initiating its recall, FDA intensified this outreach to infant formula manufacturers to inquire about their capacity and potential impacts given this developing situation. We will continue discussion with Abbott Nutrition and other infant formula manufacturers and consider all tools available to support the supply of infant formula products.

We are also partnering with the United State Department of Agriculture’s Food and Nutrition Service (FNS) to monitor the impact of the recall on the WIC Program.

**February 20, 2022**

On 2/17/2022, Abbott Nutrition initiated a voluntary recall of certain powdered infant formulas. Products made at the Sturgis facility can be found across the United States and were likely exported to other countries/locations as well. Canadian health officials have also issued a recall warning.

**February 17, 2022**

The FDA, along with CDC and state and local partners are investigating four consumer complaints of infant illness related to products from Abbott Nutrition’s Sturgis, MI facility received from 9/20/2021 to 12/18/2021. All of the cases are reported to have consumed powdered infant formula (IF) produced from Abbott Nutrition’s Sturgis, MI facility. These complaints include three reports of *Cronobacter sakazakii* infections and one report of *Salmonella* Newport infection in infants. All four cases related to these complaints were hospitalized and *Cronobacter* may have contributed to a death in one case.

FDA has initiated an onsite inspection at the facility. Findings to date include several positive *Cronobacter* results from environmental samples taken by FDA, and adverse inspectional observations by FDA investigators. A review of the firm’s internal records also indicate environmental contamination with *Cronobacter sakazakii* and the firm’s destruction of product due to the presence of *Cronobacter*.

FDA is issuing this advisory to alert consumers to avoid purchasing or using certain powdered infant formula produced in the Sturgis, MI facility.

This is an ongoing investigation and the firm is working with the FDA to initiate a voluntary recall of potentially affected product. FDA is continuing to investigate and will update this advisory should additional consumer safety information become available.

Who to Contact

**Consumers who have symptoms**should contact their health care provider to report their symptoms and receive care.

To report a **complaint**or **adverse event**(illness or serious allergic reaction), you can

Call an FDA Consumer Complaint Coordinator if you wish to speak directly to a person about your problem.
	Complete an electronic Voluntary MedWatch form online.
	Complete a paper Voluntary MedWatch form that can be mailed to FDA.Submit Questions/Get Assistance

Follow us on X

                                                                                  Content current as of:
      08/01/2022
              
              
Regulated Product(s)
		 Food & BeveragesOutbreaks of Foodborne Illness

          
                        Investigations of Foodborne Illness Outbreaks
          Public Health Advisories from Investigations of Foodborne Illness Outbreaks
          Food Safety Tips for Consumers & Retailers During an Outbreak of Foodborne Illness
          Food Safety Resources for Produce Shippers and Carriers During a Foodborne Illness Outbreak
          Outbreak Investigation Reports
          How to Report Seafood-Related Toxin and Scombrotoxin Fish Poisoning Illnesses
          About the CORE Network
          CORE Annual Reports
          CORE Publications


                        Foodborne Pathogens
 Get Email Notifications on Outbreak Investigations
                        Get email updates delivered to your inbox.
    Enter your email address to subscribe:
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop